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Background
Piperacillin is a -lactam antibiotic that is frequently used to
combat bacterial infections in patients with cystic fibrosis.
However, its use is associated with a high incidence of
delayed-type hypersensitivity reactions. Our previous stu-
dies have shown lymphocyte proliferative responses and
cytokine secretion from PBMCs in approximately 75% of
hypersensitive patients. In contrast, PBMCs from tolerant
controls were not activated by these antibiotics. Drug-
responsive T-cell clones isolated from piperacillin hyper-
sensitive patients were CD4+ and the drug derived antigen
was presented by HLA class II molecules. These data high-
light the pivotal role of T cells in mediating the piperacillin
hypersensitivity, however, little is known about TCR V
usage. Our project aims to explore the phenotype of T
cells involved in piperacillin hypersensitivity looking at the
TCR V usage, chemokine receptor expression and cyto-
kine release in both hypersensitive patients and in drug
naïve healthy donors.
Methods
PBMCs from hypersensitive patients were cultured in the
presence of piperacillin and drug-responsive T-cell clones
were generated by serial dilution. TCR V usage and che-
mokine receptor expression were analyzed by flow cyto-
metry. Cytokine release was assessed by ELISpot. Naïve
T cells from healthy donors were primed to piperacillin
using dendritic cells to present the drug antigen.
Results
A total of 20 piperacillin-specific clones were generated
from the hypersensitive patients. Most of the clones were
CD4+ and drug stimulation was associated with the secre-
tion of IFNg (85% of the clones), IL5 (65%), IL13 (35%),
perforin (60%), granzyme-B (25%) and FasL (65%). Clones
expressed high levels of CCR8, CCR4, CCR10, CXCR3,
CCR2 and CCR9. TCR V usage was by these clones was
diverse. Piperacillin-specific T-cell proliferative responses
and cytokine secretion were detected when naïve T-cells
were primed with piperacillin for 7 days. TCR V usage was
diverse with marked expansion of TCR V9 and V13.2 on
memory T-cells post priming. CDR3 spectratyping analysis
will be used to characterize whether expansion of the indi-
vidual TCR Vbs is polyclonal or oligoclonal. In on-going
experiments we are cloning T-cells from healthy volun-
teers to analyse TCR V expression.
Conclusion
These data show that piperacillin-responsive CD4+
T-cells express a diverse repertoire of TCR Vbs.
Authors’ details
1University of Liverpool, MRC Centre for Drug Safety Science, UK. 2St James’s
Hospital, Regional Adult Cystic Fibrosis Unit, UK.
Published: 18 July 2014
doi:10.1186/2045-7022-4-S3-P39
Cite this article as: Al-Attar et al.: Characterization of the TCR V
repertoire of piperacillin-specific T-cells. Clinical and Translational Allergy
2014 4(Suppl 3):P39.
1University of Liverpool, MRC Centre for Drug Safety Science, UK
Full list of author information is available at the end of the article
Al-Attar et al. Clinical and Translational Allergy 2014, 4(Suppl 3):P39
http://www.ctajournal.com/content/4/S3/P39
© 2014 Al-Attar et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
